SMTL ID : 8hid.1

HUMAN ERYTHROCYTE CATALSE COMPLEXED WITH BT-Br

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.20 Å

Oligo State

homo-tetramer

Ligands

4 x LLR: (~{S})-azanyl-[2-[[3-bromanyl-4-(diethylamino)phenyl]methyl]hydrazinyl]methanethiol(Non-covalent)

LLR.1: 6 residues within 4Å: Chain A: P.151, F.198, R.203, Y.215, K.237, F.446 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:P.151, A:F.198, A:F.446 Hydrogen bonds: A:R.203, A:K.237, A:K.237, A:K.237 LLR.3: 8 residues within 4Å: Chain B: P.151, F.198, R.203, N.213, Y.215, K.237, F.446, V.450 2 PLIP interactions: 2 interactions with chain B Water bridges: B:R.203 pi-Cation interactions: B:R.203 LLR.5: 6 residues within 4Å: Chain C: P.151, F.198, Y.215, K.237, F.446, V.450 5 PLIP interactions: 5 interactions with chain C Hydrophobic interactions: C:F.198, C:F.446, C:V.450 Hydrogen bonds: C:K.237, C:K.237 LLR.7: 8 residues within 4Å: Chain D: P.151, F.198, R.203, N.213, Y.215, K.237, F.446, V.450 2 PLIP interactions: 2 interactions with chain D Hydrophobic interactions: D:F.198, D:V.450

4 x HEM: PROTOPORPHYRIN IX CONTAINING FE(Non-covalent)

HEM.2: 26 residues within 4Å: Chain A: R.72, V.73, V.74, H.75, R.112, G.131, F.132, V.146, G.147, N.148, P.158, F.161, G.216, S.217, H.218, L.299, F.334, M.350, R.354, A.357, Y.358, T.361, H.362, R.365 Chain B: M.61, D.65 27 PLIP interactions: 27 interactions with chain A, Hydrophobic interactions: A:V.73, A:V.74, A:H.75, A:V.146, A:P.158, A:F.161, A:F.161, A:F.161, A:F.161, A:F.161, A:L.299, A:F.334, A:R.354, A:A.357, A:Y.358, A:T.361 Hydrogen bonds: A:T.361, A:T.361 Salt bridges: A:R.72, A:R.72, A:R.112, A:H.362, A:R.365 pi-Stacking: A:H.75, A:F.161 pi-Cation interactions: A:R.354 Metal complexes: A:Y.358 HEM.4: 26 residues within 4Å: Chain A: M.61, D.65 Chain B: R.72, V.73, V.74, H.75, R.112, G.131, F.132, V.146, G.147, N.148, P.158, F.161, G.216, S.217, H.218, L.299, F.334, M.350, R.354, A.357, Y.358, T.361, H.362, R.365 27 PLIP interactions: 27 interactions with chain B, Hydrophobic interactions: B:V.73, B:V.74, B:H.75, B:V.146, B:P.158, B:F.161, B:F.161, B:F.161, B:F.161, B:L.299, B:F.334, B:R.354, B:A.357, B:Y.358, B:T.361 Water bridges: B:I.332, B:T.361, B:T.361 Salt bridges: B:R.72, B:R.72, B:R.112, B:H.362, B:R.365 pi-Stacking: B:H.75, B:F.161 pi-Cation interactions: B:R.354 Metal complexes: B:Y.358 HEM.6: 25 residues within 4Å: Chain C: R.72, V.73, V.74, H.75, R.112, G.131, F.132, V.146, G.147, N.148, P.158, F.161, S.217, H.218, L.299, F.334, M.350, R.354, A.357, Y.358, T.361, H.362, R.365 Chain D: M.61, D.65 29 PLIP interactions: 29 interactions with chain C, Hydrophobic interactions: C:V.73, C:H.75, C:V.146, C:N.148, C:P.158, C:F.161, C:F.161, C:F.161, C:F.161, C:F.161, C:L.299, C:F.334, C:R.354, C:A.357, C:Y.358, C:Y.358, C:T.361 Water bridges: C:V.73, C:I.332, C:T.361 Salt bridges: C:R.72, C:R.72, C:R.112, C:H.362, C:R.365 pi-Stacking: C:H.75, C:F.161 pi-Cation interactions: C:R.354 Metal complexes: C:Y.358 HEM.8: 26 residues within 4Å: Chain C: M.61, D.65 Chain D: R.72, V.73, V.74, H.75, R.112, G.131, F.132, V.146, G.147, N.148, P.158, F.161, G.216, S.217, H.218, L.299, F.334, M.350, R.354, A.357, Y.358, T.361, H.362, R.365 29 PLIP interactions: 29 interactions with chain D, Hydrophobic interactions: D:V.73, D:V.74, D:H.75, D:V.146, D:P.158, D:F.161, D:F.161, D:F.161, D:F.161, D:F.161, D:L.299, D:F.334, D:R.354, D:A.357, D:Y.358, D:T.361 Water bridges: D:V.73, D:A.133, D:I.332, D:T.361 Salt bridges: D:R.72, D:R.72, D:R.112, D:H.362, D:R.365 pi-Stacking: D:H.75, D:F.161 pi-Cation interactions: D:R.354 Metal complexes: D:Y.358

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Cao, Y.Y. et al., A catalase inhibitor: Targeting the NADPH-binding site for castration-resistant prostate cancer therapy. Redox Biol (2023)

Release Date

2023-10-04

Peptides

Catalase: ABCD

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

C
C

D
D

Catalase

Related Entries With Identical Sequence